Cardiovascular Drugs in Pregnancy

  • Jeffrey M. Dicke


Cardiac conduction disorders during pregnancy are generally well tolerated and of minimal functional significance to the mother. However, the potential for hemodynamic decompensation and attendant pejorative effects on uterine blood flow dictates that the obstetrician be familiar with the indications for pharmacologic management of arrhythmias as well as the maternal and fetal consequences of such therapy. As is the case with many therapeutic agents, substantive knowledge of pharmacologic properties unique to the maternal/fetal unit is limited with regard to antiarrhythmic therapy. Use of these agents therefore necessitates an appreciation of the underlying pathology and therapeutic options, with decisions often based on clinical judgment rather than concrete recommendations.


Rheumatic Fever Fetal Heart Rate Rheumatic Heart Disease Acute Rheumatic Fever Placental Transfer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Greenblatt DJ, Pfeifer HJ, Ochs HR, et al: Pharmacokinetics of quinidine after intravenous, intramuscular and oral administration. J Pharmacol Exp Ther 202: 365–378, 1977PubMedGoogle Scholar
  2. 2.
    Conn HL Jr, Luchi RJ: Some cellular and metabolic considerations relating to the action of quinidine as a prototype antiarrhythmic agent. Am J Med 37: 685–699, 1964PubMedGoogle Scholar
  3. 3.
    Covinsky J0, Russo J, Kelly KL, et al: Relative bioavailability of quinidine gluconate and quinidine sulfate in healthy volunteers. J Clin Pharmacol 19: 261–269, 1979PubMedGoogle Scholar
  4. 4.
    Ueda CT, Williamson BJ, Bzindzio BS: Absolute quinidine bioavailability. Clin Pharmacol Ther 20: 260–265, 1976PubMedGoogle Scholar
  5. 5.
    Greenblatt DJ, Pfeifer JH, Ochs HR, et al: Pharmacokinetics of parenteral quinidine in humans. Clin Pharmacol Ther 21: 105, 1977Google Scholar
  6. 6.
    Palmer KH, Martin B, Baggett B, et al: The metabolic fate of orally administered quinidine gluconate in humans. Biochem Pharmacol 18: 8145–8160, 1969PubMedGoogle Scholar
  7. 7.
    Ueda CT, Hirschfeld DS, Scheinman MM, et al: Disposition kinetics of quinidine. Clin Pharmacol Ther 19: 30–36, 1976PubMedGoogle Scholar
  8. 8.
    Leahey EB Jr, Reiffel JA, Drusin RE, et al: Interaction between digoxin and quinidine. JAMA 240: 533–534, 1978PubMedGoogle Scholar
  9. 9.
    Fenster PE, Powell JR, Hager WD, et al: Onset and dose dependence of the digoxin-quinidine interaction. Am J Cardiol 45: 413, 1980Google Scholar
  10. 10.
    DiSegni E, Klein HO, David D, et al: Overdrive pacing in quinidine syncope and other long QT-interval syndromes. Arch Intern Med 140: 1036–1040, 1980Google Scholar
  11. 11.
    Koch-Weser J: Quinidine-induced hypoprothrombinemic hemorrhage in patients on chronic warfarin therapy. Ann Intern Med 68: 511–517, 1968PubMedGoogle Scholar
  12. 12.
    Cohen IS, Fick H, Cohen SI: Adverse reactions to quinidine in hospitalized patients. Findings based on data from the Boston Collaborative Drug Surveillance Program. Prog Cardiovasc Dis 20: 151–163, 1977PubMedGoogle Scholar
  13. 13.
    Hill LM, Malkasian GD: The use of quinidine sulfate throughout pregnancy. Obstet Gyneco 154: 366–368, 1979Google Scholar
  14. 14.
    Szekely P, Snaith L: Heart Disease and Pregnancy. Edinburgh, London, Churchill Livingstone, 1974Google Scholar
  15. 15.
    Bellet S: Essentials of Cardiac Arrhythmias. Diagnosis and Management. Philadelphia, WB Saunders, 1972Google Scholar
  16. 16.
    Domula VM, Weissach G, Lenk H, et al: Ober die Aus-wirkung medikament6ser Behandlung in der Schwangerschaft auf das Gerinnungspotential des Neu-geborenen. Zentralbl Gynaekol 99: 473–481, 1977Google Scholar
  17. 17.
    Mendelson CL: Disorders of the heartbeat during pregnancy. Am J Obstet Gynecol 72: 1268–1301, 1956PubMedGoogle Scholar
  18. 18.
    Grossman JI, Lubow LA, Frieden J, et al: Lidocaine in cardiac arrhythmias. Arch Inter Med 121: 396–401, 1968Google Scholar
  19. 19.
    Bigger JT, Mandel WJ: Effects of lidocaine on the elec-trophysiological properties of ventricular muscle and Purkinje fibers. J Clin Invest 49: 63–77, 1970PubMedGoogle Scholar
  20. 20.
    Lieberman NA, Harris RS, Katz RJ, et al: The effect of lidocaine on the electrical and mechanical activity of the heart. Am J Cardiol 22: 375–380, 1968PubMedGoogle Scholar
  21. 21.
    Genstenblith G, Scherlag BJ, Hope RR, et al: Effect of lidocaine on conduction in the ischemic His-Purkinje system of dogs. Am J Cardiol 43: 587–591, 1978Google Scholar
  22. 22.
    Dhingra RC, Deedwania PC, Cummings JM, et al: Elec-trophysiologic effects of lidocaine on sinus node and atrium in patients with and without sinoatrial dysfunction. Circulation 57: 448–454, 1978PubMedGoogle Scholar
  23. 23.
    Rahimtoola SH, Sinno MZ, Loeb HS, et al: Lidocaine infusion in acute myocardial infarction. Arch Intern Med 128: 416–418, 1971PubMedGoogle Scholar
  24. 24.
    Scott DB, Jebson PJ, Goodman MJ, et al: Oral lignocaine. Lancet 1: 93, 1970PubMedGoogle Scholar
  25. 25.
    Boyes RN, Scott DB, Jebson PJ, et al: Pharmacokinetics of lidocaine in man. Clin Pharmacol Ther 12: 105–116, 1971PubMedGoogle Scholar
  26. 26.
    Gianelly R, von der Groeben JO, Spivak AP, et al: Effect of lidocaine on ventricular arrhythmias in patients with coronary heart disease. N Engl J Med 277: 1215–1219, 1967PubMedGoogle Scholar
  27. 27.
    Pfeifer HJ, Greenblatt DM, Koch-Weser J: Clinical use and toxicity of intravenous lidocaine. Am Heart J 92: 168–173, 1976PubMedGoogle Scholar
  28. 28.
    Reynolds F, Taylor G: Maternal and neonatal blood concentrations of bupivacaine. A comparison with lignocaine during extradural analgesia,. Anaesthesia 25: 14–23, 1970PubMedGoogle Scholar
  29. 29.
    Biehl D. Shnider SM, Levinson S, et al: Placental transfer of lidocaine. Anesthesiology 48: 409–412, 1978PubMedGoogle Scholar
  30. 30.
    Kuhnert BR, Knapp DR, Kuhnert PM, et al: Maternal, fetal and neontal metabolism of lidocaine. Clin Pharmacol Ther 26: 213–220, 1979PubMedGoogle Scholar
  31. 31.
    Brown WV, Bell GC, Lurie AD, et al: Newborn blood levels of lidocaine and mepivacaine in the first postnatal day following maternal epidural anesthesia. Anesthesiology 42: 698–707, 1975PubMedGoogle Scholar
  32. 32.
    Biehl D, Shnider SM, Levinson G: The direct effects of circulatory lidocaine on uterine blood flow and fetal wellbeing in pregnant ewe. Can Anaesthesiol Soc J 24: 445–448, 1977Google Scholar
  33. 33.
    Shnider SM, Levinson G: Anesthesia for Obstetrics. Baltimore, Williams & Wilkins, 1979Google Scholar
  34. 34.
    Burney RG, DiFazio CA, Foster JH: Effects of pH on protein binding of lidocaine. Anesth Analg 57: 478–480, 1978PubMedGoogle Scholar
  35. 35.
    Heinonen OP, Slone D, Shapiro S: Birth Defects and Drugs in Pregnancy. Littleton, MA, Publishing Sciences Group, 1977Google Scholar
  36. 36.
    Scanlon JW, Brown WU, Weiss JB, et al: Neurobehavioral responses of newborn infants after maternal epidural anesthesia. Anesthesiology 40: 121–128, 1974PubMedGoogle Scholar
  37. 37.
    McCord MC, Taguchi JT: A study of the effect of procaine amide hydrochloride in supraventricular arrhythmias. Cir¬culation 4: 387 - 393, 1951Google Scholar
  38. 38.
    Wu D, Amat-y-Leon F, Simpson RJ, et al: Electrophysiologic studies with multiple drugs in patients with atrioventricular re-entrant tachycardias utilizing an extranodal pathway. Circulation 56: 727–736, 1977PubMedGoogle Scholar
  39. 39.
    Manion CV, Lalka D, Baer DT, et al: Absorption kinetics of procainamide in humans. J Pharm Sci 66: 981–984, 1977PubMedGoogle Scholar
  40. 40.
    Koch-Weser J: Pharmacokinetics of procainamide in man. Ann NY Acad Sci 179: 370–382, 1971PubMedGoogle Scholar
  41. 41.
    Giardina EGV, Dreyfuss J, Bigger JT Jr, et al: Metabolism of procainamide in normal and cardiac subjects. Clin Pharmacol Ther 19: 339–351, 1976PubMedGoogle Scholar
  42. 42.
    Galeazzi RL, Scheiner LB, Lockwood T, et al: The renal elimination of procainamide. Clin Pharmacol Ther 19: 55–62, 1976PubMedGoogle Scholar
  43. 43.
    Roden DM, Reele SB, Higgins SB, et al: Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects. Am J Cardio 146: 463–468, 1980Google Scholar
  44. 44.
    Fremstad D, Dahl S, Jacobsen S, et al: A new sustained release tablet formulation of procainamide. Eur J Clin Pharmacol 6: 251–255, 1973PubMedGoogle Scholar
  45. 45.
    Kayden HJ, Brodie BB, Steele JM: Procaine amide. A review. Circulation 15: 118–126, 1957PubMedGoogle Scholar
  46. 46.
    Inouye M, Millar J, Townsend JH: Agranulocytosis following maintenance dosage of Pronestyl: Report of a severe case with recovery. JAMA 147: 652–653, 1951Google Scholar
  47. 47.
    Condmi JJ, Blomgren SE, Vaughn JH: The procainamideinduced lupus syndrome. Bull Rheum Dis 20: 604–608, 1970Google Scholar
  48. 48.
    Dumesic DA, Silverman NH, Tobias S, et al: Transplacental cardioversion of fetal supraventricular tachycardia with procainamide. N Engl J Med 307: 1128–1131, 1982PubMedGoogle Scholar
  49. 49.
    Meyer J, Lackner JE, Schochet SS: Paroxysmal tachycardia in pregnancy. JAMA 94: 1901–1904, 1930Google Scholar
  50. 50.
    Metcalfe J, Ueland K: The heart and pregnancy, in Hurst JW (ed): The Heart, ed 4. New York, McGraw-Hill, 1978, p 1721Google Scholar
  51. 51.
    Conn RD: Diphenylhydantoin sodium in cardiac ar-rhythmias. N Engl J Med 272: 277–282, 1965PubMedGoogle Scholar
  52. 52.
    Atkinson AJ Jr, Davison R: Diphenylhydantoin as an antiarrhythmic drug. Annu Rev Med 25: 99–113, 1974PubMedGoogle Scholar
  53. 53.
    Bigger JT, Schmidt DH, Kutt H: Relationship between the plasma level of diphenylhydantoin sodium and its cardiac antiarrhythmic effects. Circulation 38: 363–374, 1968PubMedGoogle Scholar
  54. 54.
    Wit AL, Rosen MR, Hoffman BF: Electrophysiology and pharmacology of cardiac arrhythmias. VIII. Cardiac effects of diphenylhydantoin. Am Heart J 90: 397–404, 1975PubMedGoogle Scholar
  55. 55.
    Kutt H, Winters W, Kokenge R, et al: Diphenylhydantoin metabolism, blood levels and toxicity. Arch Neurol 11: 642–648, 1964PubMedGoogle Scholar
  56. 56.
    Gerber N, Wagner JC: Explanation of dose-dependent decline of diphenylhydantoin plasma levels by fitting to the C integrated form of the Michaelis-Menten equation. Res ommun Chem Pathol Pharmacol 3: 455–466, 1972Google Scholar
  57. 57.
    Arnold K, Gerber N: The rate of decline of diphenylhydantoin in human plasma. Clin Pharmacol Ther 11: 121–134, 1970PubMedGoogle Scholar
  58. 58.
    Goldschlager AW, Karliner JS: Ventricular standstill after intravenous diphenylhydantoin. Am Heart J 74: 410 - 412, 1967PubMedGoogle Scholar
  59. 59.
    Cloyd JC, Gumnit RJ, McLain W: Status epilepticus: The role of intravenous phenytoin. JAMA 244: 1479–1481, 1980PubMedGoogle Scholar
  60. 60.
    Dukes MNG: Anticonvulsants, in Dukes, MNG (ed): eylers Side Effects of Drugs, ed 9. Amsterdam, Excerpta edica, 1980, pp 90–101Google Scholar
  61. 61.
    Mirkin BL: Placental transfer and neonatal elimination of diphenylhydantoin. Am J Obstet Gynecol 109: 930–933, 1971PubMedGoogle Scholar
  62. 62.
    Mirkin BL: Diphenylhydantoin: Placental transport, fetal localization, neonatal metabolism, and possible teratogenic effects. J Pediatr 78: 329–337, 1971PubMedGoogle Scholar
  63. 63.
    Monson RR, Rosenberg L, Hartz SC, et al: Diphenylhydantoin and selected congenital malformations. N Engl J Med 289: 1049–1052, 1973PubMedGoogle Scholar
  64. 64.
    Hanson JW, Myrianthopoulos NC, Harvey MA, et al: Risks to the offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. J Pediatr 89: 662–668, 1976PubMedGoogle Scholar
  65. 65.
    Hanson JW, Smith DW: The fetal hydantoin syndrome. J Pediatr 87: 285–290, 1975PubMedGoogle Scholar
  66. 66.
    Mountain KR, Hirsh J, Gallus AS: Neonatal coagulation defect due to anticonvulsant drug treatment in pregnancy. Lancet 1: 265–268, 1970PubMedGoogle Scholar
  67. 67.
    Allen RW, Ogden B, Bentley FL, et al: Fetal hydantoin syndrome, neuroblastoma and hemorrhagic disease in a neonate. JAMA 244: 1464–1465, 1980PubMedGoogle Scholar
  68. 68.
    Vismara LA, Vera Z, Miller RR, et al: Efficacy of disopyramide phosphate in the treatment of refractory ventricular tachycardia. Am J Cardiol 39: 1027–1034, 1977PubMedGoogle Scholar
  69. 69.
    Deano DA, Wu D, Mautner RK, et al: The antiarrhythmic efficacy of intravenous therapy with disopyramide phosphate. Chest 71: 597–606, 1977PubMedGoogle Scholar
  70. 70.
    Heel RC, Brogden RN, Speight TM, et al: Disopyramide: A review of its pharmacological properties and therapeutic uses in treating cardiac arrhythmias. Drugs 15: 331–368, 1978PubMedGoogle Scholar
  71. 71.
    Hinderling PH, Garrett ER: Pharmacokinetics of the antiar-rhythmic disopyramide in healthy humans. J Pharmacokinet Biopharm 4: 199–230, 1976PubMedGoogle Scholar
  72. 72.
    Grant AM, Marshall RJ, Ankier SI: Some effects of disopyramide and its N-dealkylated metabolite on isolated nerve and cardiac muscle. Eur J Pharmacol 49: 389–394, 1978PubMedGoogle Scholar
  73. 73.
    Podrid PJ, Schoeneberger A, Lown B: Congestive heart failure caused by oral disopyramide. N Engl J Med 302: 614–617, 1980PubMedGoogle Scholar
  74. 74.
    Nicholson WJ, Martin CE, Gracey JG: Disopyramide-induced ventricular fibrillation. Am J Cardiol 43: 1053–1055, 1979PubMedGoogle Scholar
  75. 75.
    Shaxted EJ, Mitton PJ: Disopyramide in pregnancy: A case report. Cur Med Res Opin 6: 70–72, 1979Google Scholar
  76. 76.
    Leonard RF, Braun TE, Levy AM: Initiation of uterine con-tractions by disopyramide during pregnancy. N Engl J Med 299: 84–85, 1978PubMedGoogle Scholar
  77. 77.
    Waxman HL, Myerburg RJ, Appel R, et al: Verapamil for control of ventricular rate in paroxysmal supraventricular tachycardia and atrial fibrillation or flutter. Ann Inter Med 94: 1–6, 1981Google Scholar
  78. 78.
    Schamroth L, Krikler DM, Garrett C: Immediate effects of intravenous verapamil in cardiac arrhythmias. Br Med J 1: 660–662, 1972PubMedGoogle Scholar
  79. 79.
    Kohlhardt M, Bauer B, Krause H: New selective inhibitors of the Ca conductivity in mammalian myocardial fibers. Experientia 15: 288–289, 1972Google Scholar
  80. 80.
    Schomerus M, Spiegelhalder B, Stieren B, et al: Physiological disposition of verapamil in man. Cardiovasc Res 10:605¬612,1976Google Scholar
  81. 81.
    Singh BN, Collett JT, Chew CYC: New perspectives in the pharmacologic therapy of cardiac arrhythmias. Prog Cardiovasc Dis 22: 243–301, 1980PubMedGoogle Scholar
  82. 82.
    Barrillon A, Grand A, Gerbaux A: Treatment of the heart during pregnancy. Ann Med Interne 125: 437–445, 1974Google Scholar
  83. 83.
    Mosler KH, Jung H: Methoden der pharmakoligischen Geburtserleichterung and Uterus-Relaxation. Internationales Symposion, Bad-Aachen. Stuttgart, Georg Thieme, 1972, p 170Google Scholar
  84. 84.
    Ulmsten U: Inhibition of myometrial hyperactivity by Ca antagonists. Dan Med Bull 26: 125, 1979PubMedGoogle Scholar
  85. 85.
    Serafini PC, Petracco A, Vicosa HM Jr, et al: Arterial hypo-sensitive effect of verapamil in severe pre-eclampsia: Preliminary study. Arq Bras Cardiol 32: 57–61, 1979PubMedGoogle Scholar
  86. 86.
    Serafini PC, Petracco A, Vicosa HM Jr, et al: Verapamil and severe pre-eclampsia: Plasma and urinary levels of urea, creatinine sodium, potassium, chloride and calcium. Arq Bras Cardiol 31 (Suppl 1): 95–100, 1978PubMedGoogle Scholar
  87. 87.
    Wolff F, Breuker KH, Schlensker KH, et al: Prenatal diag-nosis and therapy of fetal heart rate anomalies: With a contribution on the placental transfer of verapamil. J Perinat Med 8: 203–208, 1980PubMedGoogle Scholar
  88. 88.
    Smith TW: Digitalis glycosides. N Engl J Med 288: 719–722, 942–946, 1973Google Scholar
  89. 89.
    Iisalo E: The clinical pharmacokinetics of digoxin. Clin Pharmacol 2: 1–16, 1977Google Scholar
  90. 90.
    White RJ, Chamberlain DA, Howard M, et al: Plasma con-centrations of digoxin after oral administration in the fasting and post prandial state. Br Med J 1: 380–381, 1971PubMedGoogle Scholar
  91. 91.
    Brown DD, Juhl RP: Decreased bioavailbility of digoxin due to antacids and kaolin pectin. N Engl J Med 295: 1034–1037, 1976PubMedGoogle Scholar
  92. 92.
    Hall WH, Shappell SD, Doherty JE: Effect of cholestyramine on digoxin absorption and excretion. Am J Cardiol 39: 213–216, 1977PubMedGoogle Scholar
  93. 93.
    Lindenbaum J, Maulitz RM, Butler VP: Inhibition of digoxin absorption by neomycin. Gastroenterology 71: 399–404, 1976PubMedGoogle Scholar
  94. 94.
    Juhl RP, Summers RW, Guillary JK, et al: Effect of sul-fapyridine on digoxin bioavailability. Clin Pharmacol Ther 20: 387–394, 1976PubMedGoogle Scholar
  95. 95.
    Gault MH, Jeffrey JR, Chirito E, et al: Studies of digoxin dosage, kinetics, and serum concentrations in renal failure and review of the literature. Nephron 17: 161–187, 1976PubMedGoogle Scholar
  96. 96.
    Marcus FI, Burkhalter L, Cuccia C, et al: Administration of tritiated digoxin with and without a loading dose: A metabolic study. Circulation 34: 865–874, 1966PubMedGoogle Scholar
  97. 97.
    Rogers MC, Willerson JT, Goldblatt A, et al: Serum digoxin concentration in the human fetus, neonate and infant. N Engl J Med 287: 1010 1013, 1972Google Scholar
  98. 98.
    Doherty JE, Perkins WH: Tissue concentration and turnover of tritiated digoxin in dogs. Am J Cardio117: 47–52, 1966Google Scholar
  99. 99.
    Hernandez A, Stauss AW, Burton RM, et al: The effects of long term administration of 3H-digoxin to the pregnant ewe upon the cardiovascular hemodynamics of fetal lamb. Am Heart J 85: 511–517, 1973PubMedGoogle Scholar
  100. 100.
    Saarikoski S: Placental transfer and fetal uptake of 3H-di¬goxin in humans. Br J Obstet Gynaecol 83: 879–884, 1976PubMedGoogle Scholar
  101. 101.
    Soyka LF: Digoxin: Placental transfer, effects on the fetus, and therapeutic use in the newborn. Clin Perinato12: 23–35, 1975Google Scholar
  102. 102.
    Okita GT, Plotz EJ, Davis ME: Placental transfer of radioactive digitoxin in pregnant women and its fetal distribution. Circ Res 4: 387–380, 1956Google Scholar
  103. 103.
    Padeletti L, Porclani MC, Scimone G: Placental transfer of digoxin (beta methyl-digoxin) in man. Int J Clin Pharmacol Biopharmaco117: 82–83, 1979Google Scholar
  104. 104.
    Whitsett JA, Wallick ET: [3H] Ouabain binding and Na +¬K+-ATPase activity in human placenta. Am J Physiol 238: E38–E45, 1980Google Scholar
  105. 105.
    Weaver JB, Pearson JF: Influence of digitalis on time of onset and duration of labour in women with cardiac disease. Br Med J 3: 519 - 520, 1973PubMedGoogle Scholar
  106. 106.
    Potondi A: Congenital rhabdomyoma of the heart and intrauterine digitalis poisoning. J Foren Sci 11: 81–88, 1966Google Scholar
  107. 107.
    Sherman JL, Lock RU: Transplacental neonatal digitalis intoxication. Am J Cardiol 6: 834–837, 1960Google Scholar
  108. 108.
    Szekely P, Desmond GJ: Heart disease and pregnancy. Cur Problems Cardiol 4: 1–74, 1979Google Scholar
  109. 109.
    Mendelson CL: Cardiac Disease in Pregnancy. Phiadelphia, FA Davis, 1960Google Scholar
  110. 110.
    Levy M, Granit L, Laufer N: Excretion of drugs in human milk. N Engl J Med 297: 789, 1977PubMedGoogle Scholar
  111. 111.
    Loughnan PM: Digoxin excretion in human breast milk. J Pediatr 92: 1019–1020, 1978PubMedGoogle Scholar
  112. 112.
    Robertson EG: The natural history of oedema during pregnancy. J Obstet Gynaecol Br Commonw 78: 520–529, 1971PubMedGoogle Scholar
  113. 113.
    Gray MJ: Use and abuse of thiazides in pregnancy. Clin Obstet Gynecol 11: 568–578, 1968PubMedGoogle Scholar
  114. 114.
    Kraus GW, Marchese JR, Yen SSC: Prophylactic use of hydrochlorothiazide in pregnancy. JAMA 198: 1150–1154, 1966PubMedGoogle Scholar
  115. 115.
    Bletka M, Hlavaty V, Trnkova M, et al: Volume of whole blood and absolute amount of serum proteins in the early stage of late toxemia of pregnancy. Am J Obstet Gynecol 106: 10–13, 1970Google Scholar
  116. 116.
    Chesley LC: Plasma and red cell volumes during pregnancy. Am J Obstet Gynecol 112: 440–450, 1972PubMedGoogle Scholar
  117. 117.
    MacGillivray I: The significance of blood pressure and body water changes. Scot Med J 12: 237–245, 1967PubMedGoogle Scholar
  118. 118.
    Gant NF, Madden JD, Siiteri PK, et al: The metabolic clearance rate of dehydroisoandrosterone sulfate: III. The effect of thiazide diuretics in normal and future pre-eclamptit pregnancies,. Am J Obstet Gyneco1123: 159–163, 1975PubMedGoogle Scholar
  119. 119.
    Ueland K, McAnulty JH, Ueland FR, et al: Special considerations in the use of cardiovascular drugs. Clin Obstet Gynecol 24: 809–923, 1981PubMedGoogle Scholar
  120. 120.
    Minkowitz S, Soloway HB, Hall JE: Fatal hemorrhagic pancreatitis following chlorothiazide administration in pregnancy. Obstet Gynecol 24: 337–342, 1964PubMedGoogle Scholar
  121. 121.
    Pritchard JA, Walley PJ: Severe hypokalemia due to prolonged administration of chlorothiazide during pregnancy. Am J Obstet Gynecol 81: 1 241–1244, 1961Google Scholar
  122. 122.
    Schifrin BS, Spellacy WN, Little WA: Maternal death associated with excessive ingestion of a chlorothiazide diuretic. Obstet Gynecol 34: 215–220, 1969PubMedGoogle Scholar
  123. 123.
    Garnet JD: Placental transfer of chlorothiazide. Obstet Gynecol 21: 123–125, 1963PubMedGoogle Scholar
  124. 124.
    Lindheimer MD, Katz AL: Sodium and diuretics in pregnancy. JAMA 198: 1150–1154, 1966Google Scholar
  125. 125.
    Anderson JB: The effect of diuretics in late pregnancy on the newborn infant. Acta Paediatr Shand 59: 659–663, 1970Google Scholar
  126. 126.
    Rodriguez SU, Leikin SL, Hiller MC: Neonatal thrombocytopenia associated with antepartum administration of thiazide drugs. N Engl J Med 270: 881–884, 1964PubMedGoogle Scholar
  127. 127.
    Crosland DM, Flowers CE Jr: Chlorothiazide and its relationship to neonatal jaundice. Obstet Gynecol 22: 500–504, 1963PubMedGoogle Scholar
  128. 128.
    Alstatt LB: Transplacental hyponatremia in the newborn infant. J Pediatr 66: 785–788, 1965Google Scholar
  129. 129.
    Anderson GC, Hanson TM: Chronic fetal bradycardia. Obstet Gynecol 44: 896–898, 1974PubMedGoogle Scholar
  130. 130.
    Riva E, Farina P, Togoni G, et al: Pharmacokinetics of furosemide in gestosis of pregnancy. Eur J Clin Pharmacol 14: 361–366, 1978PubMedGoogle Scholar
  131. 131.
    Ladner E, Brinkman CR, Weston P, et al: Dynamics of uterine circulation in pregnant and non-pregnant sheep. Am J Physio 1218: 257–263, 1970Google Scholar
  132. 132.
    Barden TP, Stander RW: Effects of adrenergic blocking agents and catecholamines in human pregnancy. Am J Obstet Gynecol 102: 226–235, 1968PubMedGoogle Scholar
  133. 133.
    Evans GH, Wilkinson GR, Shand DG: The disposition of propranolol. IV. A dominant role for tissue uptake in the dose-dependent extraction of propranolol by the perfused rat liver. J Pharmacol Exp Ther 186: 447–454, 1973PubMedGoogle Scholar
  134. 134.
    Shand DG, Nuckolls EM, Oates JA: Plasma propranolol levels in adults with observations in four children. Clin Pharmacol Ther 11: 112–120, 1970PubMedGoogle Scholar
  135. 135.
    Riddiough MA: Preventing, detecting and managing adverse reactions of antihypertensive agents in the ambulant patient with hypertension. Am J Hosp Pharm 34: 465–479, 1977PubMedGoogle Scholar
  136. 136.
    Barden TP, Stander RW: Myometrial and cardiovascular effects of an adrenergic blocking drug in human pregnan-cy. Am J Obstet Gyneco1101: 91–99, 1968Google Scholar
  137. 137.
    Datta S, Kitzmiller JL, Ostheimer GW: Propranolol and parturition. Obstet Gynecol 51: 577–581, 1978PubMedGoogle Scholar
  138. 138.
    Pruyn SC, Phelan JP, Buchanan GC: Long term propranolol therapy in pregnancy: Maternal and fetal outcome. Am J Obstet Gynecol 135: 485–489, 1979PubMedGoogle Scholar
  139. 139.
    Gladstone GR, Hordof A, Gersony WM: Propranolol ad-ministration during pregnancy: Effects on the fetus. J Pediatr 86: 962–964, 1975PubMedGoogle Scholar
  140. 140.
    Turnstall MB: The effect of propranolol on the onset of breathing at birth. Br J Anesthesiol 41: 792, 1969Google Scholar
  141. 141.
    Habib A, McCarthy JS: Effects on the neonate of Pro-pranolol administered during pregnancy. J Pediatr 91: 808–811, 1977PubMedGoogle Scholar
  142. 142.
    Cottrill CM, McAllister RG Jr, Gelles L: Propranolol therapy during pregnancy, labor and delivery: Evidence for transplacental drug transfer and impaired neonatal drug dis-position. J Pediatr 91: 812–814, 1977PubMedGoogle Scholar
  143. 143.
    Martin LE, Hopkins R, Bland R: Metabolism of labetalol by animals and man. Br J Clin Pharmacol 3 (Suppl 3): 695–710, 1976PubMedGoogle Scholar
  144. 144.
    Frishman W, Halprin S: Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 7. New horizons in beta-adrenoreceptor blockade therapy: Labetalol. Am Heart J 98: 660–665, 1979PubMedGoogle Scholar
  145. 145.
    Brittain RT, Levy GP: A review of the animal pharmacology of labetalol, a combined α and ß adrenoreceptor blocking drug. Br J Clin Pharmacol (Suppl 3 ): 681–684, 1976Google Scholar
  146. 146.
    Lunell NO, Hjendahl P, Fredholm BB, et al: Acute effects of labetalol on maternal metabolism and uteroplacental circulation in hypertension of pregnancy, in Riley A, Symmonds EM (eds): The Investigation of Labetalol in the Man-agement of Hypertension in Pregnancy. Princeton, Excerpta Medica, 1982, p 34Google Scholar
  147. 147.
    Symonds EM, Lamming GD, Jadoul F, et al: Clinical and biochemical aspects of the use of labetalol in the treatment of hypertension in pregnancy: Comparison with methyldopa, in Riley A, Symonds EM (eds): The Investigation of Labetalol in the Management of Hypertension in pregnancy. Princeton, Excerpta Medica, 1982, p 62Google Scholar
  148. 148.
    Redman CWG: A controlled trial of the treatment of hyper¬tension in pregnancy: Labetalol compared with methyldopa, in Riley A, Symonds EM (eds): The Investigation of Labetolol in the Management of Hypertension in Pregnancy. Princeton, Excerpta Medica, 1982, p 101Google Scholar
  149. 149.
    Sandstrom B: Antihypertensive treatment with the adre-nergic beta-receptor blocker metoprolol during pregnancy. Gynecol Obstet Invest 9: 195–204, 1978Google Scholar
  150. 150.
    Rubin PC, Butters L, Low R, et al: Atenolol in the treatment of essential hypertension during pregnancy. Br J Clin Pharmacol 14: 279–281, 1982PubMedGoogle Scholar
  151. 151.
    Thorley KJ, McAinsh J, Cruickshank JM: Atenolol in the treatment of pregnancy-induced hypertension. Br J Clin Pharmacol 12: 725–730, 1981PubMedGoogle Scholar
  152. 152.
    Lunell NO, Persson B, Aragon G, et al: Circulatory and metabolic effects of acute beta,-blockade in severe pre-eclampsia. Acta Obstet Gynecol Shand 58: 443–445, 1979Google Scholar
  153. 153.
    Snyder SW, Wheeler AS, James FM: The use of nitro¬glycerin to control severe hypertension of pregnancy during caesarean section. Anesthesiology 51: 563–564, 1979PubMedGoogle Scholar
  154. 154.
    Diaz SF, Marx GF: Placental transfer of nitroglycerin [Letter]. Anesthesiology 51: 475–476, 1979PubMedGoogle Scholar
  155. 155.
    Lewis PE, Cefalo RC, Naulty JS, et al: Placental transfer and fetal toxicity of sodium nitroprusside [Abstract], in: Proceedings of the 24th Annual Meeting of the Society for Gynecologic Investigation, Tucson, Arizona. Basel, S. Karger, 1977, p 46Google Scholar
  156. 156.
    Ring G, Krames E, Shnider S, et al: Comparison of nitroprusside and hydralazine in hypertensive pregnant ewes. Obstet Gynecol 50: 598–602, 1977PubMedGoogle Scholar
  157. 157.
    Stempel JE, O’Grady JP, Morton MJ, et al: Use of sodium nitroprusside in complications of gestational hypertension. Obstet Gyneco 160: 533–538, 1982Google Scholar
  158. 158.
    Paull J: Clinical report of the use of sodium nitroprusside in severe preeclampsia. Anaesth Intensive Care Med 13: 72, 1975Google Scholar

Copyright information

© Plenum Publishing Corporation 1985

Authors and Affiliations

  • Jeffrey M. Dicke

There are no affiliations available

Personalised recommendations